文献速递类风湿关节炎

血清蛋白特征与类风湿关节炎发病的关联

Association of a Serum Protein Signature With Rheumatoid Arthritis Development.
PubMed 文献 · Arthritis Rheumatol · 2020-11-10

机器学习识别出可区分进展者的临床前蛋白特征(AUC 0.913,准确率91.2%),该特征在发病中位30.9个月前即可检出,并提示Toll样受体2激活及TNF、IL-1产生为关键事件。

要点

  • 临床前血清蛋白特征可区分RA进展者与高危个体,不受ACPA状态影响。
  • 该特征在发病中位30.9个月前已可检出,提示发病前数年即存在蛋白组改变。
  • 网络分析提示TLR2激活及TNF、IL-1产生是RA进展前的关键事件。

核心结论

  • RA临床前阶段血清蛋白组改变可早于发病数年出现,该特征有助于对高危个体分类并揭示发病相关分子通路。

主要发现

  • 临床前蛋白特征区分RA进展者与高危者的曲线下面积为0.913,准确率91.2%,且不依赖ACPA状态。
  • 该特征在发病中位30.9个月前的血清样本中即可检出。
  • 网络分析提示Toll样受体2激活及肿瘤坏死因子和白细胞介素-1产生是RA进展前的关键事件。

关键数值与推荐

  • 蛋白特征区分进展者与高危者的AUC为0.913,准确率91.2%。
  • 特征可于发病中位30.9个月前检出。

临床怎么用

  • 血清蛋白特征可能用于识别RA高危个体,但尚需外部验证后方可进入临床决策。
  • TLR2及TNF、IL-1通路提示的临床前机制可为未来干预提供靶点线索。

局限性

  • 研究样本量较小(进展者17例),且局限于北美原住民RA患者一级亲属队列。
  • 原文未报告外部验证队列及临床转化所需的具体阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The pathophysiologic events that precede the onset of rheumatoid arthritis (RA) remain incompletely understood. This study was undertaken to identify changes in the serum proteome that precede the onset of RA, with the aim of providing new insights into the pathogenic mechanisms that lead to its development. METHODS: In a cohort of first-degree relatives of Indigenous North American RA patients, the SomaScan proteomics platform was used to determine the levels of 1,307 proteins in multiple longitudinal serum samples from 17 individuals who were followed up prospectively to the time of disease onset. Proteomic signatures from this group of individuals (designated the progressor group) were compared to those in a group of individuals who were considered at risk of developing RA, stratified as either positive (n = 63) or negative (n = 47) for anti-citrullinated protein antibodies (ACPAs) (designated the at-risk group). Machine learning was used to identify a protein signature that could accurately classify those individuals at highest risk of future RA development. RESULTS: A preclinical proteomic signature that differentiated RA progressors from at-risk individuals, irrespective of ACPA status, was identified (area under the curve 0.913, accuracy 91.2%). Importantly, the predictive preclinical proteomic signature was present not only in serum samples obtained close to the onset of RA, but also in serum samples obtained a median of 30.9 months prior to onset. Network analysis implicated the activation of Toll-like receptor 2 and production of tumor necrosis factor and interleukin-1 as key events that precede RA progression. CONCLUSION: Alterations in the serum proteome in the preclinical phase of RA can emerge years prior to the onset of disease. Our findings suggest that the serum proteome provides a rich source of proteins serving both to classify at-risk individuals and to identify molecular pathways involved in the development of clinically detectable RA.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. O'Neil LJ, Spicer V, Smolik I, et al. Association of a Serum Protein Signature With Rheumatoid Arthritis Development. Arthritis Rheumatol. 2020. PMID: 32770634. doi:10.1002/art.41483

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。